Versant Vantage II GP-GP, LLC
SEC CIK 1839789 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| LENZ | LENZ Therapeutics, Inc. | 10% | 764.1K | $3.06M | $26.60M | 7 | 2021-06-29 | 2025-09-30 |
Most active insiders at LENZ, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Versant Vantage II GP-GP, LLC | 10% | — | $10.35M |
| 2 | Olsson Shawn | Chief Commercial Off | — | $261.0K |
| 3 | Schimmelpennink Evert B. | Pres, CEO, Sec, Dir | $251.4K | — |
| 4 | MCCOLLUM JAMES W | Dir | $239.3K | — |
| 5 | Chevallard Daniel R. | CFO | $114.3K | — |
| 6 | George Jeffrey P. | Dir | $49.9K | — |
Transactions 7
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2025-10-02 | 2025-09-30 | LENZ | LENZ Therapeutics, Inc. | Versant Vantage II GP-GP, LLC | 10% | S - Sale | $46.01 | -92.0K | 764.1K | -11% | -$4.23M |
| M | 2025-10-02 | 2025-09-30 | LENZ | LENZ Therapeutics, Inc. | Versant Vantage II GP-GP, LLC | 10% | S - Sale | $46.01 | -132.9K | 1.05M | -11% | -$6.12M |
| 2025-07-01 | 2025-06-27 | LENZ | LENZ Therapeutics, Inc. | Versant Vantage II GP-GP, LLC | 10% | S - Sale | $30.47 | -200.0K | 1.77M | -10% | -$6.09M | |
| I | 2025-06-12 | 2025-06-10 | LENZ | LENZ Therapeutics, Inc. | Versant Vantage II GP-GP, LLC | 10% | S - Sale | $29.00 | -350.0K | 1.25M | -22% | -$10.15M |
| DI | 2021-07-01 | 2021-06-29 | LENZ | LENZ Therapeutics, Inc. | Versant Vantage II GP-GP, LLC | 10% | P - Purchase | $17.00 | +180.0K | 1.71M | +12% | +$3.06M |
| DI | 2021-07-01 | 2021-06-29 | LENZ | LENZ Therapeutics, Inc. | Versant Vantage II GP-GP, LLC | 10% | C - Cnv Deriv | — | +1.53M | 1.53M | New | — |
| D | 2021-07-01 | 2021-06-29 | LENZ | LENZ Therapeutics, Inc. | Versant Vantage II GP-GP, LLC | 10% | C - Cnv Deriv | — | +12.34M | 14.71M | +522% | — |
Purchase Sale Sale after option exercise All abbreviations